estrogen receptor

The drug giant will be responsible for globally developing and commercializing the compound, called Erso, currently in preclinical development.

The funding will be used to advance the firm's lead drug candidate, OP-1250, into a Phase I/II trial of ER-positive, HER2-negative breast cancer.  

The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.

A Phase I trial of the combination produced a higher response rate in fulvestrant-pretreated patients than capivasertib alone.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.